For questions about BMS medicines during this time,
please call
THREE 1L Indications in Thoracic Cancers
With the foundation of OPDIVO® (nivolumab) + YERVOY® (ipilimumab)
Select an OPDIVO + YERVOY-based treatment
option to view clinical information.
1L NSCLC
With no EGFR or ALK tumor aberrations.
*Two cycles of platinum-doublet chemo.
1L=first-line; ALK=anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor; mNSCLC=metastatic non-small cell lung cancer; MPM=malignant pleural mesothelioma; NSCLC=non-small cell lung cancer;
